Evidence map›Paper›PMID 30883338›Full record

ArticleCancer biomarkers : section A of Disease markers2019

Immunohistochemical assessment of cyclin D1 and p53 is associated with survival in childhood malignant peripheral nerve sheath tumor.

Malgorzata A Krawczyk, Gabrielle Karpinsky, Ewa Izycka-Swieszewska, Anna Gabrych, Michal Kunc, Aleksandra Fatyga, Monika Garstka, Malgorzata Styczewska, Ewa M Sokolewicz, Agnieszka Szlagatys-Sidorkiewicz and 2 more

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 3 pooled it
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 3 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Malgorzata A KrawczykDepartment of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
Gabrielle KarpinskyChildren's Hospital of Michigan, Detroit, MI, USA.
Ewa Izycka-SwieszewskaDepartment of Pathology and Neuropathology, Medical University of Gdansk, Gdansk, Poland.
Anna GabrychDepartment of Pediatrics, Hematology and Oncology, University Clinical Centre, Gdansk, Poland.
Michal KuncDepartment of Pathomorphology, Medical University of Gdansk, Gdansk, Poland.
Aleksandra FatygaDepartment of Pediatrics, Hematology and Oncology, University Clinical Centre, Gdansk, Poland.
Monika GarstkaThe English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.
Malgorzata StyczewskaThe English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.
Ewa M SokolewiczThe English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.
Agnieszka Szlagatys-SidorkiewiczDepartment of Pediatrics, Gastroenterology, Hepatology and Nutrition, Medical University of Gdansk, Gdansk, Poland.
Bernarda KazanowskaThe English Division Pediatric Oncology Scientific Circle, Medical University of Gdansk, Gdansk, Poland.
Ewa BienDepartment of Pediatrics, Hematology and Oncology, Medical University of Gdansk, Gdansk, Poland.
Gdańsk Medical University · PLUniversity Clinical Centre · PLChildren's Hospital of Michigan · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant peripheral nerve sheath tumor (MPNST) is rare, aggressive soft tissue sarcoma which may affect children.

objectiveWe aimed to assess prognostic significance of immunohistochemical (IHC) markers, osteopontin, fibronectin, survivin, cyclin D1 and p53, in pediatric MPNST.

methodsA total of 26 pediatric MPNST patients were enrolled in the current study with a median follow-up of 51 months. IHC staining using commercially available monoclonal antibodies were employed to detect analyzed antigens on tissue microarrays. Eventually, all markers were subclassified to high (H) and low (L) expression categories in all analyzed tumors.

resultsHigh IHC expressions of survivin, cyclin D1, osteopontin, fibronectin, and p53 were detected in 18 (69.2%), 13 (50%), 16 (61.5%), 16 (61.5%), and 13 (50%) tumors, respectively. A significant correlation was demonstrated between cyclin D1 and osteopontin (p= 0.004). Both markers were associated with neurofibromatosis type 1 (NF1) status (p= 0.041 and p= 0.037, respectively). H-fibronectin was more prevalent in deeply located tumors (p= 0.046). None of the markers was associated with IRS stage, age at diagnosis, and tumor size. Univariate analysis identified IRS stage, regional lymph node metastases, NF1, and cyclin D1 as variables associated with overall survival (OS), whereas tumor depth, osteopontin, and cyclin D1 - for relapse-free survival (RFS). Subsequent multivariate analysis identified cyclin D1 and p53 as independent variables predicting RFS, whereas cyclin D1 and regional lymph nodes status were independent predictors for OS.

Indexed as

Biomarkers, TumorAdolescentAge FactorsChildChild, PreschoolCyclin D1FemaleHumansImmunohistochemistryInfantInfant, NewbornMaleNeoplasm StagingNerve Sheath NeoplasmsPrognosisProportional Hazards ModelsBiomarkers, TumorCyclin D1Tumor Suppressor Protein p53

Identifiers

PMID30883338
PMCPMC13082518
OpenAlexW2921324177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.